Long-acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults with HIV-1 Infection (ATLAS-2M), 48-Week Results: a Randomised, Multicentre, Open-Label, Phase 3b, Non-Inferiority StudyEdgar T. Overton,Gary Richmond,Giuliano Rizzardini,Hans Jaeger,Catherine Orrell, Firaya Nagimova,Fritz Bredeek,Miguel Garcia Deltoro,Susan Swindells,Jaime Federico Andrade-Villanueva,Alexander Wong,Marie-Aude Khuong-Josses,Rodica Van Solingen-Ristea,Veerle van Eygen,Herta Crauwels,Susan Ford,Christine Talarico,Paul Benn,Yuanyuan Wang,Krischan J. Hudson,Vasiliki Chounta,Amy Cutrell,Parul Patel,Mark Shaefer,David A. Margolis, Kimberly Y. Smith,Simon Vanveggel,William SpreenThe Lancet（2020）引用 168|浏览61暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
